Advice
Following a full submission
pregabalin (Lyrica ®) is not recommended for use within NHS Scotland for the treatment of central neuropathic pain in adults.
In a randomised controlled trial pregabalin was superior to placebo in terms of the primary efficacy variable, the weekly mean pain score.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by the SMC.
The licence holder has indicated their decision to resubmit.
Download detailed advice77KB (PDF)
Medicine details
- Medicine name:
- pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica)
- SMC ID:
- 389/07
- Indication:
- Central neuropathic pain in adults
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 August 2007